• Oncolytics Biotech presented new pelareorep data from an ongoing anal cancer study at the Society for Immunotherapy of Cancer 2026 Annual Meeting.
• The Phase 1/2 trial combines pelareorep with a checkpoint inhibitor in previously treated patients with unresectable squamous cell anal cancer.
• Treatment increased HPV-specific immune responses associated with tumor shrinkage; efficacy signals suggested better responses than the currently approved therapy.
• Management is seeking strategic collaborations targeting HPV-associated cancers, a potential $3 billion to $5 billion market based on internal estimates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040930PRIMZONEFULLFEED9870036) on November 04, 2026, and is solely responsible for the information contained therein.